Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.33 |
| ▸ | QPCT | Q16769 | 1/20 | 0.31 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.30 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2408208 | 0.85 | HSP90AA1 (0.34) | HSP90AA1HSP90AB1MEN1ALDH1A1KMT2A | |
| SCHEMBL5494056 | 0.70 | ALDH1A1 (0.42) | HSP90AA1MEN1ALDH1A1KMT2AHCAR2 | |
| SCHEMBL2408801 | 0.68 | ALDH1A1 (0.35) | HRH3MEN1ALDH1A1KMT2A | |
| SCHEMBL3356506 | 0.67 | KMT2A (0.62) | HSP90AA1MEN1ALDH1A1KMT2A | |
| SCHEMBL2407279 | 0.63 | LMNA (0.35) | ALDH1A1 | |
| SCHEMBL14822490 | 0.62 | HCAR2 (0.43) | MEN1ALDH1A1KMT2AHCAR2 | |
| SCHEMBL13331949 | 0.61 | KCNH2 (0.35) | HSP90AA1HSP90AB1HRH3HCAR2 | |
| SCHEMBL5378655 | 0.59 | — | — | |
| SCHEMBL15233144 | 0.59 | — | — | |
| SCHEMBL16950288 | 0.58 | AOC1 (0.41) | HRH3QPCTQPCTLALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8022061-B2 | 5-(Methoxymethyl)-1-(5-methyl-4-(thiophen-2-yl)pyrimidin-2-yl)-N-(pyridin-4-ylmethyl)-1H-pyrazole-4-carboxamide; for the treatment or prevention of type 2 diabetes and type 2 diabetes-related conditions | AMGEN INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-20080153778-A1 | N-aryl pyrazole compounds, compositions, and methods for their use | AMGEN INC. | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153778-A1 | N-aryl pyrazole compounds, compositions, and methods for their use | GLP1R, GPR119, NAT1 | HSP90AA1 3593/4885HSP90AB1 3312/4885HRH3 1957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.